Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. Twist Bioscience Corporation has a collaboration agreement with Pandion Therapeutics, Inc. to apply its antibody optimization platform for a targeting arm of a bispecific antibody. The company was founded in 2013 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone800-719-0671
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$25.43 million
Profitability
Miscellaneous
Employees289
Next Earnings Date12/18/2019 (Estimated)
OptionableNot Optionable
Twist Bioscience (NASDAQ:TWST) Frequently Asked Questions
What is Twist Bioscience's stock symbol?
Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."
How were Twist Bioscience's earnings last quarter?
Twist Bioscience Corp (NASDAQ:TWST) posted its quarterly earnings results on Thursday, August, 1st. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.83) by $0.09. The firm had revenue of $13.60 million for the quarter, compared to analyst estimates of $12.51 million. Twist Bioscience had a negative net margin of 204.63% and a negative return on equity of 168.45%. View Twist Bioscience's Earnings History.
When is Twist Bioscience's next earnings date?
What guidance has Twist Bioscience issued on next quarter's earnings?
Twist Bioscience updated its FY 2019 earnings guidance on Thursday, August, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $52-53 million, compared to the consensus revenue estimate of $51.54 million.
What price target have analysts set for TWST?
4 analysts have issued 1 year target prices for Twist Bioscience's shares. Their predictions range from $25.99 to $26.66. On average, they expect Twist Bioscience's share price to reach $26.3250 in the next year. This suggests that the stock has a possible downside of 6.2%. View Analyst Price Targets for Twist Bioscience.
What is the consensus analysts' recommendation for Twist Bioscience?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Twist Bioscience.
Has Twist Bioscience been receiving favorable news coverage?
News headlines about TWST stock have been trending positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Twist Bioscience earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View News Stories for Twist Bioscience.
Are investors shorting Twist Bioscience?
Twist Bioscience saw a increase in short interest during the month of July. As of July 15th, there was short interest totalling 1,951,300 shares, an increase of 24.3% from the June 15th total of 1,569,800 shares. Based on an average trading volume of 366,600 shares, the days-to-cover ratio is presently 5.3 days. Approximately 14.0% of the company's stock are sold short. View Twist Bioscience's Current Options Chain.
Who are some of Twist Bioscience's key competitors?
Some companies that are related to Twist Bioscience include China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Crispr Therapeutics (CRSP), Acceleron Pharma (XLRN), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD), Regenxbio (RGNX), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO) and Momenta Pharmaceuticals (MNTA).
What other stocks do shareholders of Twist Bioscience own?
Who are Twist Bioscience's key executives?
Twist Bioscience's management team includes the folowing people:
- Dr. Emily Marine Leproust, Co-Founder, Pres, CEO & Director (Age 45)
- Mr. James M. Thorburn, Chief Financial Officer (Age 64)
- Mr. Mark Daniels Esq., Sr. VP, Chief Legal Officer, Gen. Counsel, Chief Ethics & Compliance Officer and Sec. (Age 56)
- Mr. William Charles Banyai, COO & Director (Age 64)
- Mr. Bill Peck, Chief Technology Officer (Age 59)
When did Twist Bioscience IPO?
(TWST) raised $75 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers.
Who are Twist Bioscience's major shareholders?
Twist Bioscience's stock is owned by a variety of of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (6.15%), BlackRock Inc. (4.71%), Vanguard Group Inc. (3.25%), Emerald Advisers LLC (1.79%), Emerald Mutual Fund Advisers Trust (1.61%) and Farallon Capital Management LLC (0.95%). Company insiders that own Twist Bioscience stock include James M Thorburn, Keith Crandell and Patrick Weiss. View Institutional Ownership Trends for Twist Bioscience.
Which institutional investors are selling Twist Bioscience stock?
TWST stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A.. Company insiders that have sold Twist Bioscience company stock in the last year include James M Thorburn and Patrick Weiss. View Insider Buying and Selling for Twist Bioscience.
Which institutional investors are buying Twist Bioscience stock?
TWST stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Vanguard Group Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Farallon Capital Management LLC, ARK Investment Management LLC and Asymmetry Capital Management L.P.. View Insider Buying and Selling for Twist Bioscience.
How do I buy shares of Twist Bioscience?
Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Twist Bioscience's stock price today?
One share of TWST stock can currently be purchased for approximately $28.07.
How big of a company is Twist Bioscience?
Twist Bioscience has a market capitalization of $913.96 million and generates $25.43 million in revenue each year. The company earns $-71,230,000.00 in net income (profit) each year or ($25.51) on an earnings per share basis. Twist Bioscience employs 289 workers across the globe.View Additional Information About Twist Bioscience.
What is Twist Bioscience's official website?
How can I contact Twist Bioscience?
Twist Bioscience's mailing address is 455 MISSION BAY BOULEVARD SOUTH SUITE 545, SAN FRANCISCO CA, 94158. The company can be reached via phone at 800-719-0671 or via email at [email protected]
MarketBeat Community Rating for Twist Bioscience (NASDAQ TWST)
MarketBeat's community ratings are surveys of what our community members think about Twist Bioscience and other stocks. Vote "Outperform" if you believe TWST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TWST will underperform the S&P 500 over the long term. You may vote once every thirty days.
